TABLE 1.
Resistance pattern | No. of antimicrobial classes | No. (%) of isolates | ||
---|---|---|---|---|
2014 (n = 5) |
2021 (n = 47) |
2022 (n = 139) |
||
AUG-AMP-AZI-XNL-AXO-CHL-NAL-STR-FIS-TET-SXT | 8 | 0 (0) | 0 (0) | 1 (0.7) |
AMP-AZI-XNL-AXO-CHL-GEN-NAL-STR-FIS-TET-SXT | 8 | 0 (0) | 0 (0) | 2 (1.4) |
AMP-AZI-XNL-AXO-CHL-NAL-STR-FIS-TET-SXT | 8 | 0 (0) | 0 (0) | 8 (5.8) |
AMP-XNL-AXO-CHL-CIP-NAL-STR-FIS-TET-SXT | 8 | 0 (0) | 0 (0) | 1 (0.7) |
AMP-XNL-AXO-CHL-GEN-NAL-STR-FIS-TET-SXT | 7 | 0 (0) | 9 (19.1) | 28 (20.1) |
AMP-FOX-XNL-AXO-CHL-NAL-STR-FIS-TET-SXT | 7 | 0 (0) | 1 (2.1) | 3 (2.2) |
AMP-AZI-XNL-AXO-CHL-NAL-FIS-TET-SXT | 7 | 0 (0) | 0 | 1 (0.7) |
AMP-XNL-AXO-CHL-GEN-NAL-STR-FIS-TET | 7 | 0 (0) | 2 (4.3) | 2 (1.4) |
AMP-XNL-AXO-CHL-NAL-STR-FIS-TET-SXT | 7 | 0 (0) | 23 (48.9) | 64 (33.1) |
AMP-FOX-XNL-AXO-CHL-NAL-STR-FIS-TET | 7 | 0 (0) | 0 (0) | 1 (0.7) |
AMP-XNL-AXO-CHL-NAL-STR-FIS-TET | 7 | 0 (0) | 2.1 | 2 (1.4) |
AMP-XNL-AXO-GEN-NAL-STR-FIS-TET-SXT | 6 | 0 (0) | 4.3 | 0 (0) |
AMP-XNL-AXO-GEN-NAL-STR-FIS-TET | 6 | 0 (0) | 0 (0) | 14 (10.1) |
AMP-XNL-AXO-CHL-NAL-FIS-TET-SXT | 6 | 0 (0) | 0 (0) | 1 (0.7) |
AMP-XNL-AXO-NAL-STR-FIS-TET-SXT | 6 | 0 (0) | 1 (2.1) | 1 (0.7) |
AMP-CHL-NAL-FIS-TET-SXT | 5 | 0 (0) | 1 (2.1) | 0 (0) |
AMP-XNL-AXO-CHL-NAL | 4 | 0 (0) | 0 (0) | 1 (0.7) |
STR-TET-SXT | 3 | 0 (0) | 1 (2.1) | 0 (0) |
NAL | 1 | 0 (0) | 1 (2.1) | 0 (0) |
Pan-susceptibleb | 0 | 5 (100) | 5 (10.6) | 9 (6.5) |
MDR (≥3 antimicrobial classes)b | 0 (0) | 41 (87.2) | 130 (93.5) |
AMP, ampicillin; AUG, amoxicillin-clavulanic acid; AXO, ceftriaxone; AZI, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; FIS, sulfisoxazole; FOX, cefoxitin; GEN, gentamicin; NAL, nalidixic acid; STR, streptomycin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; XNL, ceftiofur; MDR, multi-drug resistance.
There was a significant difference (P < 0.05) in the number of S. Infantis exhibiting the corresponding antibiotic resistance pattern in 2014, 2021, and 2022.
The highest proportion is indicated in bold.